Biosims making slow progress battling blockbusters for market share; FibroGen raising $300M
⇨ Bloomberg has a report out today that illustrates just how slowly biosimilars are able to penetrate some of the world’s biggest franchises. Some say the market is tilted against them, with branded drugs winning and keeping preferred status, despite their higher costs.
⇨ FibroGen just joined the long line of public biotechs that have been cashing in on higher stock prices. The company is selling $300 million in shares after racking up some big gains.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.